SRP327595 PRJNA741822 Genome level reveals that probiotics supplementation can alleviate the clinical symptoms of patients with coronary heart disease Recently, researchers have attempted to positively steer the development of metabolic functions through targeted administration of specific probiotics, thereby preventing and improving related cardiovascular diseases. We conducted a 6-month randomized, double-blind, placebo-controlled clinical trial. Sixty patients with coronary heart disease were randomly divided into the probiotic group (n=36; Probio-M8, statins lipid-lowering drugs and metoprolol) and placebo group (n=24; placebo, statins lipid-lowering drugs and metoprolol). After 6 months of treatment, the angina pectoris of the placebo and probiotic groups were significantly improved, and the improvement effect of patients in the probiotic group was more obvious. The in-depth metagenomic analysis showed that significantly more species-level genome bins (SGBs) of Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobacterium bifidum, and Ruminococcaceae bacterium were identified in the fecal metagenomes of the probiotic group, while the abundances of SGBs representing the species Roseburia inulinivorans and Eubacterium sp. CAG:115 decreased significantly.